Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-06700841 On Qtc Interval In Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-06700841 On Qtc Interval In Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brepocitinib (Primary)
  • Indications Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Dec 2022 Results (from 5 clinical trials; NCT02310750 NCT03236493 NCT03656952 NCT02969018 NCT02974868 ) assessing Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients published in the Clinical Pharmacology in Drug Development
    • 25 Feb 2019 Status changed from recruiting to completed.
    • 28 Nov 2018 Planned End Date changed from 3 Dec 2018 to 6 Jan 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top